Challenger Limited (CFIGY) Fair Value & Analysis
Financial Services · US · Market cap $3.0B
Challenger Limited
CFIGY · US
Fair value as of: Jun 26, 2026
From 20 valuation models · updated 28 days ago
Fair value updated Jun 26, 2026, revised from $32.15 to $25.24 (−21.5%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $41.65 – $43.70 · fair‑value band $18.93 – $31.55 · the $43.70 price screens above the $25.24 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Challenger Limited (CFIGY) currently trades at $43.70, while our model-based Fair Value estimate is $25.24, implying the stock looks roughly 42.2% overvalued today. We read business quality at 61/100 (solid quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Challenger Limited generated revenue of $2.8B at a net margin of 16.4%. Revenue declined 16.9% year over year. It earns a return on equity of 11.6%. Net debt stands at $7.6B. Fundamentals as of Jun 26, 2026
Our scenario range runs from $18.93 (bear case) to $31.55 (bull case); at $43.70, the current price sits above that range. The share trades about 18% below its 52-week high and 5% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at 33% fair-value upside, at -42%, CFIGY screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Challenger Limited is a publicly owned investment manager. The company also provides retirement services to its clients. It manages equity mutual funds. The firm invests into the public equity markets across the world. Challenger Limited was founded in 1985 and is based in Australia, Asia and United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Challenger Limited reported revenue of $751M in FY2025 versus $3.0B in FY2021, a compound −29.5%/yr. Reported net income was $192M in FY2025, compounding −24.5%/yr from FY2021.
Is CFIGY fairly valued? → Check now
Similar stocks
10 more Insurance - Life stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| China Life Insurance Company 601628 | ¥32.82 | ¥65.64 | +100% |
| Ping An Insurance (Group) Company 601318 | ¥51.98 | ¥103.96 | +100% |
| AIA Group 1299 | HK$70.25 | HK$93.13 | +33% |
| Manulife Financial Corporation MFC | C$54.00 | C$58.76 | +9% |
| Aflac Incorporated A1FL34 | R$590.00 | R$409.57 | -31% |
| MetLife, Inc METB34 | R$439.50 | R$455.81 | +4% |
| Great-West Lifeco Inc GWO | C$81.92 | C$69.65 | -15% |
| Life Insurance Corporation LICI | ₹442.40 | ₹590.43 | +33% |
| Fubon Financial Holding 2881 | 118.00 TWD | 100.66 TWD | -15% |
| Cathay Financial Holding 2882 | 100.00 TWD | 200.00 TWD | +100% |
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Challenger Limited (CFIGY) undervalued?
What is the fair value of CFIGY?
What is the quality score of CFIGY?
What is the revenue of Challenger Limited (CFIGY)?
What is the net profit margin of CFIGY?
Does Challenger Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Challenger Limited analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.